Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population by Vafaeimanesh, J. et al.
Research Article
Helicobacter pylori Infection and Insulin Resistance in
Diabetic and Nondiabetic Population
Jamshid Vafaeimanesh,1 Mahmoud Parham,1
Mohammadreza Seyyedmajidi,2 and Mohammad Bagherzadeh1
1 Clinical Research Development Center, Department of Internal Medicine, Qom University of Medical Sciences, Qom, Iran
2Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences, Gorgan, Iran
Correspondence should be addressed to Mohammad Bagherzadeh; m bagherzadeh3@yahoo.com
Received 27 July 2014; Accepted 11 October 2014; Published 23 October 2014
Academic Editor: Tomasz Brzozowski
Copyright © 2014 Jamshid Vafaeimanesh et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Helicobacter pylori (HP) is a commonworldwide infection with known gastrointestinal and nongastrointestinal complications. One
of the gastrointestinal side effects posed for this organism is its role in diabetes and increased insulin resistance. The aim of this
study was to evaluate the association between HP and insulin resistance in type 2 diabetic patients and nondiabetics. This cross-
sectional study was carried out from May to December 2013 on 211 diabetic patients referred to diabetes clinic of Shahid Beheshti
Hospital of Qom and 218 patients without diabetes.HP was evaluated using serology method and insulin resistance was calculated
using HOMA-IR. The prevalence of H. pylori infection was 55.8% and 44.2% in diabetics and nondiabetics (𝑃 = 0.001). The study
population was divided into two HP positive and negative groups. Among nondiabetics, insulin resistance degree was 3.01 ± 2.12
and 2.74±2.18 inHP+ andHP− patients, respectively (𝑃 = 0.704). Oppositely, insulin resistance was significantly higher in diabetic
HP+ patients rather than seronegative ones (4.484±2.781 versus 3.160±2.327,𝑃 = 0.013). In diabetic patients, in addition to higher
prevalence of HP, it causes a higher degree of insulin resistance.
1. Introduction
The most common infection in the world, especially in
developing countries, is Helicobacter pylori (HP) infection
which is an etiological factor for developing peptic ulcer,
gastric cancer, and acute polymorphonuclear infiltration in
the gastric mucosa [1, 2]. The mononuclear infiltration is
characterized by the local production and systemic diffu-
sion of proinflammatory cytokines affecting remote tissues
and organic systems [3, 4]. This systemic inflammation
causes some extragastrointestinal side effects ofHP including
ischemic heart disease [1], sideropenic anemia [5], idiopathic
thrombocytopenic purpura [6], neurologic diseases [7], and
hepatobiliary diseases [8].
It has been shown that HP infection plays a role in some
endocrine disorders, such as autoimmune thyroid diseases,
diabetes, and primary hyperparathyroidism and may have a
high prevalence among patients with diabetes [9, 10]. The
association between HP and diabetes was first explored in
Simon et al.’s study [11]. Recently, a meta-analysis [12] showed
HP infection was increased to 1.33 among patients with
diabetes. In addition, some studies have shown an increased
incidence of diabetes among people with HP infection so
that the first report that HP infection increased incidence of
diabetes was in a study by Jeon et al. [13] using a prospective
cohort of 782 Latino individuals >60 years of age.
Etiopathogenesis of HP infection in diabetic patients has
not been defined clearly. However, this hypothesis is now
proposed that HP infection is more prevalent among people
with diabetes but it is not clear whether diabetics have more
susceptibility to this infection or HP infection increases the
susceptibility to diabetes. One of the hypotheses about HP
infection as a risk factor for diabetes is increased insulin
resistance in these patients.
As insulin resistance can develop in the presence of
inflammation or as a result of alterations in counter regu-
latory hormones that affect insulin, HP may thus promote
insulin resistance by inducing chronic inflammation and
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Table 1: The characteristics of the patients with respect to seropositivity forHP.
Parameter HP–𝑁 (%) HP+𝑁 (%) 𝑃 value
Gender (female/male) Nondiabetic 57 (52.3%)/51 (46.8%) 52 (47.7%)/58 (53.2%) 0.489
Diabetic 47 (65.3%)/25 (34.7%) 88 (63.3%)/51 (36.7%) 0.778
Insulin resistance risk factors
Age (year) Nondiabetic 39.18 ± 12.44 39.88 ± 12.50 0.669
Diabetic 51.5 ± 8.3 53.5 ± 9.0 0.128
BMI Nondiabetic 26.25 ± 5.04 26.24 ± 4.33 0.871
Diabetic 29.4 ± 4.9 28.8 ± 4.8 0.427
Exercise degree
>150min per week Nondiabetic 4 (3.7) 2 (1.8) 0.299
Diabetic 2 (2.9%) 11 (7.9%) 0.478
30–150min per week Nondiabetic 14 (13.0) 7 (6.4)
Diabetic 4 (5.7%) 10 (7.2%)
<30min per week Nondiabetic 27 (25.0) 37 (33.6)
Diabetic 15 (21.4%) 26 (18.7%)
No Nondiabetic 63 (58.3) 64 (58.2)
Diabetic 51 (72.9%) 92 (66.2%)
affecting insulin-regulating gastrointestinal hormones [14,
15]. The first direct evidence for an association between
chronic HP infection and insulin resistance rose from
Aydemir et al.’s study [15] showing higher homeostatic model
assessment-estimated insulin resistance (HOMA-IR) scores
in HP positive (HP+) individuals. In contrast, some studies
have not shown this association [16].
Regarding these conflicting findings and the fact that
proving a causal role betweenHP infection and insulin resis-
tance increase has important role in controlling the important
and common diseases such as diabetes and nonalcoholic
fatty liver, we aimed to evaluate the association between HP
infection and insulin resistance in type 2 diabetic patients and
nondiabetics.
2. Materials and Methods
2.1. Patients. This cross-sectional study was carried out from
May toDecember 2013 on 211 type 2 diabetic patients referred
to diabetes clinic of Shahid Beheshti Hospital of Qom and 218
nondiabetic patients. Type 2 diabetic patients with diabetes
duration of >5 years and receiving oral hypoglycemic drugs
participated in this study as case group and the control
group was selected from attendants with the patient referring
to the endocrinology clinic. Diabetes diagnosis was based
on American Diabetes Association’s criteria (fasting plasma
glucose diagnostic of ≥126mg/dL, 2-hour plasma glucose
value of ≥200mg/dL, and HbA1c of ≥6.5%) [17].
In case of receiving insulin, pregnancy, smoking, history
of HP treatment (proton-pump inhibitor, H2 blocker, and
bismuth) or receiving antibiotics in the previous 6 months,
surgery on upper GI tract, gastric cancer, and using non-
steroidal anti-inflammatory drugs, patients were excluded
from the study. Then, the presence of HP infection patients
was evaluated. After 8-hour fasting overnight, blood samples
were taken at 4∘C and, right after sampling, the serum was
centrifuged at 2000 rpm for 15 minutes. Anti-HP IgG anti-
body was measured by ELISA kit, made by Padtan Elm Co,
Iran. In case of serum titer above 30AU/mL, it was considered
positive. Serum insulin was measured using ELISA kit,
DiaMetra Co, Italy.We calculated and compared homeostasis
model assessment of insulin resistance (HOMA-IR) in this
studymultiplying the fasting glucose value (mg/dL) by serum
insulin value in each person and then dividing it by 405.
2.2. Statistical Analysis. Data analysis was performed by SPSS
version 16.0 using descriptive statistics, mean, standard devi-
ation, percentage, and frequency.The analysis was performed
by 𝑡-test, Chi-square test, and Fisher’s exact test.
2.3. Ethics. All individuals signed informed consent prior to
their enrolment in the study. Also, the study was planned
according to the ethical guidelines following the Declaration
of Helsinki and Ethics Committee of Qom University of
Medical Sciences approved it.
3. Results
In this study, 211 diabetic and 218 nondiabetic subjects were
studied. Female/male ratio in patients with diabetes and
nondiabetic patients was 135/76 and 109/109, respectively.
In patients with diabetes, the prevalence of HP infection
was 55.8% while it was 44.2% in nondiabetics. The study
population was divided into two HP positive and negative
groups. As it is shown in Table 1, patients with diabetes and
nondiabetic subjects were not significantly different in terms
of gender, age, body mass index, and physical activity level.
Among nondiabetic subjects, HOMA-IR score was 3.01±
2.12 and 2.74 ± 2.18 in HP+ and HP− patients, respectively.
Although insulin resistance was higher in HP+ individuals,
this difference was not statistically significant (𝑃 = 0.704).
Oppositely, insulin resistance was significantly higher inHP+
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Table 2: Insulin resistance, glycemic control, and medication type in patients with respect to seropositivity for HP.
Parameter HP− HP+ 𝑃 value
Serum insulin (𝜇IU/mL) Nondiabetic 11.65 ± 4.88 12.71 ± 4.64 0.708
Diabetic 6.97 ± 2.64 10.12 ± 4.72 0.002
HOMA-IR score Nondiabetic 2.74 ± 2.18 3.01 ± 2.12 0.704
Diabetic 3.16 ± 2.32 4.48 ± 2.78 0.013
FBS (mg/dL) Nondiabetic 92.75 ± 11.70 92.58 ± 14.92 0.915
Diabetic 173.43 ± 61.32 180.12 ± 64.27 0.468
Lipid profile
HDL (mg/dL) Nondiabetic 54.23 ± 19.79 56.55 ± 20.05 0.390
Diabetic 69.2 ± 29.2 60.7 ± 26.7 0.037
LDL (mg/dL) Nondiabetic 83.26 ± 29.75 85.96 ± 32.67 0.525
Diabetic 107.1 ± 43.2 116.0 ± 51.7 0.212
TG (mg/dL) Nondiabetic 142.63 ± 112.27 140.81 ± 95.20 0.897
Diabetic 224.2 ± 100.2 229.3 ± 114.6 0.747
Cholesterol (mg/dL) Nondiabetic 161.16 ± 42.68 157.50 ± 38.86 0.509
Diabetic 205.1 ± 63.2 207.3 ± 67.4 0.8
diabetic patients rather than seronegative ones (4.48 ± 2.78
versus 3.16 ± 2.32, 𝑃 = 0.013).
As shown in Table 2, although the blood sugar level in
HP+ diabetic patients was higher than HP− subjects, the
difference was not statistically significant (𝑃 = 0.468).
Evaluation of lipid profile showed that the only significant
difference between both groups was lower HDL among HP+
diabetic patients (60.7 ± 26.7 versus 69.2 ± 29.2, 𝑃 = 0.037)
(Table 2).
4. Discussion
In this study the rate of HP seropositivity among diabetic
and nondiabetic patients was patients and nondiabetics and
the difference between the groups was statistically significant
(𝑃 = 0.001) [10]. Another seroprevalence study in United
Arab Emirates showed that positive antibody titer for HP
infection (IgA > 250) in diabetics was 63.3% compared to
nondiabetics 48.1%; similarly, according to IgG antibody titer
(IgG> 300),HP infectionwas determined in diabetic patients
at a rate of 76.7% compared to an infection rate of 64.8%
in nondiabetics [18]. Candelli and colleagues found that the
prevalence ofHP infectionwas higher in diabetics (24%) than
in controls of similar age, gender, and socioeconomical status
after three years of follow-up and the reinfection rate was
higher in diabetic patients [19].
In contrast to these studies, other researchers did not
report this association [20–22]. It is not clear whether diabet-
ics have more susceptibility to this infection or HP infection
increases the susceptibility to diabetes. One of the hypotheses
about HP infection as a risk factor for diabetes is increased
insulin resistance in these patients. In some studies, people
with diabetes are considered at risk of HP infection and it
is suggested that autonomic neuropathy and poor glycemic
control might have a significant role in this field [10].
An association between HP infection and changes
in gastric motility, acid secretion, and diabetes-induced
impairment of cellular and humoral immunity has been
reported in several studies [11–13, 23]. Also, altered glucose
metabolism may produce chemical changes in the gastric
mucosa due to altered glucose metabolism [24] and individ-
uals with diabetes are more frequently exposed to pathogens
than their healthy counterparts as they regularly attend
hospital settings [25].
In contrast, some investigators believe that HP infection
is a more favorable condition for developing diabetes. For
example, it is commonly believed that the chronic inflam-
mation induced by HP infection is strongly associated to the
pathogenesis of diabetes, which is linked to a general activa-
tion of the innate immune system, and a chronic, cytokine-
mediated state of low-grade inflammation. Proinflammatory
cytokines affect many tissues which cause recognizable fea-
tures of diabetes [26].
Inflammation of the adipose tissue is considered a key
factor in the pathogenesis of insulin resistance and 𝛽-cell
potential autoinflammation impairs insulin secretion in dia-
betes.HP-induced gastritis can affect the secretion of gastric-
related hormones such as leptin and ghrelin, as well as gastrin
and somatostatin, which may influence a predisposition to
diabetes [27, 28].
One of the hypotheses aboutHP infection as a risk factor
for diabetes is increased insulin resistance in these patients.
One of the first studies in this fieldwas inAydemir et al.’s study
in 2005 on 63 HP+ and 27 HP− patients. Age, gender, and
BMIwere not different between both groups. HOMA-IR level
was 1.73±1.1 inHP− group, whereas it was 2.56±1.54 inHP+
group. This study addressed the association between HP and
insulin resistance, although the sample size was small [15].
In 2009 Gunji and colleagues [29] have studied 1107
nondiabetic Japanese patients and found that among those
with higher insulin resistance score (HOMA-IR ≥ 2.5), the
prevalence of the HP was higher (39.4 versus 28.7%, 𝑃 =
0.027). Although people with higher insulin resistance were
fewer (99 cases versus 1008), a recent systematic review for the
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association between HP infection and quantitative indexes
of insulin resistance showed a positive association between
HP infection and insulin resistance, independent of several
confounders [30].
On the contrary, opposite studies exist too. For example,
Gillum stated that there is no consistent association between
HP infection and diabetic prevalence or variables of the
insulin resistance syndrome in American men 40–74 years of
age [31]. Also, Malamug and colleagues’ study in 2014 was in
accordance with that study [16].
In our study insulin resistance was significantly higher
in diabetic patients with HP infection (4.484 ± 2.781 ver-
sus 3.160 ± 2.327, 𝑃 = 0.013). In contrast, although
in HP+ nondiabetic patients insulin resistance was higher
than seronegative individuals (3.01 ± 2.12 versus 2.74 ±
2.18), it was not statistically significant (𝑃 = 0.704). These
findings suggest the hypothesis that HP infection does not
increase the risk of diabetes in nondiabetic population. But in
diabetics, HP is more prevalent and also HP+ diabetics have
a greater HOMA-IR score and need higher levels of insulin
for glycemic control.
This study warrants further studies aimed at clarifying
which HP strain is involved in insulin resistance, whether
or not inflammation is involved, and whether inflammatory
cytokines are present (or genetics for proinflammatory hap-
lotypes). Also will cure of the pathogen alter the insulin
resistance?
However, further studies are needed to investigate the
association between HP and insulin resistance because
understanding the causal role of this organism in insulin
resistance is important for controlling the important and
common diseases such as diabetes and nonalcoholic fatty
liver.
5. Conclusion
HP infection does not significantly increase insulin resistance
in nondiabetic individuals but in diabetic patients; in addi-
tion to higher prevalence of HP, it causes a higher degree of
insulin resistance and needs higher levels of insulin for the
same control similar to seropositive subjects.
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